ESMO 2025 Highlights Transformative Advances in Cancer Treatment: ADCs Move to Earlier Disease Settings While AI Integration Accelerates
核心洞察
The European Society for Medical Oncology (ESMO) 2025 Congress in Berlin showcased significant advances in antibody-drug conjugates (ADCs), with trastuzumab deruxtecan demonstrating superior efficacy in early-stage HER2-positive breast cancer (搜索) with 67% pathologic complete response rates.
Artificial intelligence integration into clinical workflows gained momentum, with AI-driven chest X-ray tools achieving 96% accuracy in lung cancer (搜索) detection and spatial awareness models enabling nuanced tumor microenvironment interpretation.
Previously undruggable targets like KRAS G12D (搜索) showed promising therapeutic responses, with novel inhibitors achieving up to 41% objective response rates in heavily pretreated pancreatic cancer (搜索) patients.
The European Society for Medical Oncology (ESMO) 2025 Congress in Berlin marked a pivotal moment in cancer care, showcasing transformative advances that are reshaping treatment paradigms across multiple tumor types. With over 35,000 attendees and nearly 3,000 abstracts presented, the meeting highlighted a convergence of technology and biology where artificial intelligence meets immunotherapy and precision medicine intersects with novel drug modalities.
ADCs Advance to Curative Intent Settings
Antibody-drug conjugates emerged as a dominant theme at ESMO 2025, with over 130 abstracts demonstrating the modality's evolution from salvage therapy to curative intent. The most significant breakthrough came from AstraZeneca's DESTINY-Breast05 and DESTINY-Breast11 trials, which positioned trastuzumab deruxtecan (T-DXd) as a game-changing therapy in HER2-positive breast cancer (搜索).
In the DESTINY-Breast05 adjuvant study, T-DXd improved invasive disease-free survival and disease-free survival by 53% compared with trastuzumab emtansine (T-DM1). The DESTINY-Breast11 neoadjuvant trial demonstrated even more striking results, with T-DXd followed by standard HER2 (搜索)-targeted therapy achieving a pathologic complete response rate of 67.3% versus 56.3% with standard care (p=0.003).
Safety profiles remained manageable, with interstitial lung disease occurring in approximately 9.6% of patients, though mostly grade 1-2 and reversible. Cardiac toxicity rates were reassuringly low, addressing previous concerns about ADC tolerability in curative settings.
Beyond breast cancer, ADCs showed transformative potential across tumor types. In muscle-invasive bladder cancer (搜索), perioperative enfortumab vedotin combined with pembrolizumab reduced the risk of death by 53% in cisplatin-ineligible patients, representing a 50% improvement in overall survival versus surgery alone. For metastatic triple-negative breast cancer, datopotamab deruxtecan improved progression-free survival by 38% in the first-line setting.
Artificial Intelligence Transforms Clinical Practice
AI integration moved from promise to practical implementation at ESMO 2025. The CREATE study, presented by Qure.ai (搜索) and AstraZeneca, exemplified this potential with an AI-driven chest X-ray tool that identified 96% of lung cancer (搜索) cases, including early-stage disease in non-smokers—a population often missed by traditional screening.
Advanced AI tools demonstrated impressive capabilities across multiple applications. Google's Med-Gemini and Alpaca showed remarkable accuracy in whole-slide imaging, while spatial awareness models like SMMILe enabled nuanced interpretation of tumor microenvironments. These developments promise to democratize precision oncology, particularly in resource-limited settings.
However, implementation challenges remain significant. University of Bern Professor of Digital Pathology Inti Zlobec noted that only 5% of pathology labs in Switzerland are fully digitized, with similar figures across Europe. The cost of upgrading laboratory information systems is estimated at €5 million per site, highlighting the economic barriers to widespread adoption.
Breakthrough in Previously Undruggable Targets
ESMO 2025 marked significant progress in targeting previously undruggable cancer mutations, particularly KRAS variants. The G12D mutation, present in approximately 39% of pancreatic cancer (搜索) patients, showed promising therapeutic responses with novel inhibitors.
GFH375, a selective KRAS G12D (搜索) inhibitor, demonstrated a 41% objective response rate and 97% disease control in heavily pretreated pancreatic cancer (搜索) patients in a Phase I/II study. Similarly, Incyte's INCB161734 showed objective response rates up to 34% in heavily pretreated pancreatic ductal adenocarcinoma, representing a breakthrough in a mutation long considered intractable.
HRS-7058, a KRAS G12C (搜索) inhibitor, demonstrated promising activity in non-small cell lung cancer (搜索) and colorectal cancer (搜索), including in patients previously treated with other KRAS inhibitors, suggesting potential for sequential targeting strategies.
ctDNA Enables Precision Treatment Monitoring
Circulating tumor DNA assays emerged as dynamic biomarkers for therapeutic monitoring and minimal residual disease detection. The technology enables real-time therapy adjustments and more precise treatment decisions, with advances in digital droplet PCR and next-generation sequencing pushing detection sensitivity boundaries.
The IMvigor011 Phase III study in bladder cancer (搜索) demonstrated that ctDNA-positive patients receiving adjuvant atezolizumab had significantly improved disease-free and overall survival, while ctDNA-negative patients could potentially avoid unnecessary treatment. In metastatic colorectal cancer (搜索) with BRAF V600E mutations, ctDNA analysis showed high concordance with tissue testing and demonstrated that early changes in ctDNA levels correlated with treatment response and resistance evolution.
The DYNAMIC-III study in stage III colon cancer validated ctDNA as both a prognostic marker and tool for treatment de-escalation, with ctDNA-negative patients achieving excellent outcomes without intensive chemotherapy, reducing both toxicity and cost.
Immunotherapy Innovation Beyond Checkpoint Inhibition
While checkpoint inhibitors revolutionized oncology, resistance remains a formidable barrier. ESMO 2025 showcased multiple strategies to overcome this challenge through novel immune modulators and combination approaches.
Abalos Therapeutics (搜索)' ABX-001, an arenavirus-based immunotherapy, activates both innate and adaptive immunity systemically, achieving complete remissions in preclinical models with favorable safety profiles. CatalYm's visugromab, targeting GDF-15 (搜索), restored sensitivity to PD-1 (搜索) inhibitors in refractory tumors, delivering responses lasting beyond 32 months in NSCLC and urothelial cancer while also mitigating cancer cachexia.
Simcha Therapeutics' decoy-resistant IL-18 (ST-067) enhanced the efficacy of bispecific T-cell engagers in solid and hematologic malignancies, addressing intrinsic T-cell limitations. Transgene and BioInvent's oncolytic virus BT-001 combined with pembrolizumab induced tumor shrinkage in both injected and distant lesions.
Regional Research Dynamics Shift Global Landscape
Asia's rising influence in global oncology innovation became evident at ESMO 2025, with several studies conducted exclusively in China featured in Presidential Symposia. The RC48-C016 Phase III trial demonstrated that disitamab vedotin combined with toripalimab significantly outperformed chemotherapy as first-line treatment for HER2 (搜索)-expressing advanced urothelial carcinoma, with superior progression-free survival (13.1 months vs. 6.5 months).
This marked the first time clinical research by a China-based study team in urological oncology was selected for presentation in an ESMO Congress Presidential Symposium, reflecting the region's growing footprint in ADCs, bispecific antibodies, and KRAS-targeted therapies.
Meanwhile, Europe faces ongoing challenges maintaining R&D competitiveness, with regulatory updates including Joint Clinical Assessment requirements for new oncology drugs, overworked trial sites, and lengthier contracting timelines contributing to declining trial activity.
Metabolic Targeting Emerges as Therapeutic Pillar
Cancer metabolism, long considered "undruggable," emerged as a viable target at ESMO 2025. Faeth Therapeutics (搜索)' Phase 2 DICE trial in platinum-resistant ovarian cancer (搜索) demonstrated a 34% reduction in progression risk and 45% extension in progression-free survival when sapanisertib was added to paclitaxel.
By simultaneously inhibiting PI3K, mTORC1, and mTORC2, this multi-node strategy addresses metabolic plasticity—a key driver of resistance. These findings suggest metabolic targeting may join immunotherapy and ADCs as a foundational pillar of oncology, particularly in tumors linked to obesity and metabolic disorders.
Looking Forward: Integration and Implementation
ESMO 2025 crystallized three key imperatives for oncology's future: integration of technology and biology through AI and multi-omics, diversification of therapeutic modalities beyond traditional approaches, and personalization at scale through biomarker-driven strategies.
As ESMO President Fabrice André emphasized in his opening address, "The pace of change in oncology demands more than reflection; it calls for renewal." The challenge now lies in translating these innovations from congress halls to clinics while ensuring access, affordability, and equity in a rapidly evolving landscape.